PTPRC and neoplasm: This was accompanied by a dose-associated statistically significant on-target reduction of PD-1 surface protein in tumor CD45+ leukocytes (Figure 2B), including CD4+ and CD8+ T cells (Figures 2C, D), for mice treated with PH-762.